Iakovos Kritikos is a senior research informatics and automation professional working in R&D at Eli Lilly in Boston, where he designs and leads scalable, compliant informatics platforms that integrate multimodal scientific data across global research environments. His work spans high‑throughput data architectures, laboratory automation, AI‑enabled inspection systems, and resilient data pipelines supporting life‑science discovery, significantly improving reproducibility, throughput, and time‑to‑data. He holds dual degrees in Electrical and Computer Engineering from the National Technical University of Athens, an MSc and MRes in Biomedical Engineering from Imperial College London, and a Master of Engineering Management from Duke University, and is currently pursuing a Doctorate in Business Administration in Health at UCL, focused on the quantitative evaluation of AI and technology investments in drug discovery. His research background includes machine learning for biomedical signal analysis, time‑frequency modeling of blood–brain barrier permeability, virtual and augmented reality systems for neuroengineering, and embedded and computational systems for miniature mass spectrometry. He has authored peer‑reviewed publications across neuroscience, biomedical engineering, virtual reality, and AI in pharma R&D, and has presented his work at leading international conferences. His career reflects a consistent focus on bridging advanced engineering and strategic decision‑making.
Iakovos Kritikos is a senior research informatics and automation professional working in R&D at Eli Lilly in Boston, where he designs and leads scalable, compliant informatics platforms that integrate multimodal scientific data across global research environments. His work spans high‑throughput data architectures, laboratory automation, AI‑enabled inspection systems, and resilient data pipelines supporting life‑science discovery, significantly improving reproducibility, throughput, and time‑to‑data. He holds dual degrees in Electrical and Computer Engineering from the National Technical University of Athens, an MSc and MRes in Biomedical Engineering from Imperial College London, and a Master of Engineering Management from Duke University, and is currently pursuing a Doctorate in Business Administration in Health at UCL, focused on the quantitative evaluation of AI and technology investments in drug discovery. His research background includes machine learning for biomedical signal analysis, time‑frequency modeling of blood–brain barrier permeability, virtual and augmented reality systems for neuroengineering, and embedded and computational systems for miniature mass spectrometry. He has authored peer‑reviewed publications across neuroscience, biomedical engineering, virtual reality, and AI in pharma R&D, and has presented his work at leading international conferences. His career reflects a consistent focus on bridging advanced engineering and strategic decision‑making.